Vitamin E significantly reduced AST of -19.43 U/L, ALT of -28.91, ALP of -10.39 U/L, steatosis of -0.54, inflammation of -0.20, and hepatocellular ballooning of -0.34 compared with the control group in NAFLD patients. Vitamin E treatment with NASH adult patients showed obvious reductions in not only AST of -13.91 U/L, ALT of -22.44 U/L, steatosis of -0.67, inflammation of -0.20, but also fibrosis of -0.30 compared with control treatment. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.